IPMT procedure can benefit patients with acute deep vein thrombosis

Patients with acute deep vein thrombosis (DVT) develop potentially dangerous blood clots and can suffer severe leg pain and swelling. Doctors with Virginia Interventional & Vascular Associates (VIVA) report success over the past two years in treating acute DVT patients with a procedure called isolated pharmacomechanical thrombolysis (IPMT), which destroys clots much faster than traditional therapies.

VIVA performs the two-hour, minimally invasive procedure with the FDA-approved Trellis® Peripheral Infusion System. Using medical images to help guide Trellis to the right spot, VIVA's interventional radiologists isolate the clot with balloons positioned at each end of the catheter, infuse the clot with fibrinolytic (clot-dissolving) medication, break it up with a tiny rotating wire, and aspirate the remaining particles.

Dr. John D. Statler, a board-certified, fellowship-trained, interventional radiologist with VIVA, says the procedure offers several advantages over traditional therapies. Traditional treatments include anticoagulant medication. This prevents the clot from growing and protects the lungs, but does not dissolve the clot, relying on the body to break it down over time. Catheter-directed thrombolysis, which dissolves clots by delivering thrombolytic medication through catheters, requires a 24- to 72-hour intensive care hospital stay.

"We can destroy the clot and relieve pain for most patients within a couple of hours after starting the procedure," Dr. Statler stated. "It requires an overnight hospital stay, rather than intensive care for several days, and the risk of bleeding is lower than for catheter-directed thrombolysis."

Dr. Statler notes the safety and effectiveness of IPMT have been documented in several clinical studies. The American College of Chest Physicians has endorsed the procedure for select patients with extensive acute proximal DVT.

While DVT is not fatal by itself, a blood clot that travels to the pulmonary arteries, a pulmonary embolism, can be deadly, according to the Office of the Surgeon General (OSG). Together, DVT and pulmonary embolism contribute to at least 100,000 deaths each year. The OSG, along with the National Quality Forum and The Joint Commission, has called for more aggressive treatment of DVT.

Source:

Virginia Interventional & Vascular Associates

Comments

  1. Anastasia Anastasia United States says:

    A common way of treating Deep Vein Thrombosis is the administration of medicines. The most common types of drugs which are administrated are the following: Anticoagulants: these substances are used in order to reduce the possibility of the blood to form clots; in addition, they stop the existing clots from getting bigger but hey do not have the power to break up these blood clots. These drugs can be injected under the skin or they can be administrated orally or using s tube which is introduced into a vein. This kind of treatment usually lasts for a couple of months, but there are some situations in which the length of the treatment can be modified: the period can be shorter when the clop appeared after a surgery and it can be longer when the patient suffered from this disorder previously or when he also suffers of other diseases, such as cancer.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New prediction model helps identify epilepsy risk after stroke